Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/INCYTE-CORPORATION-9675/news/Incyte-gibt-japanische-Zulassung-von-Pemazyre-Pemigatinib-fur-die-Behandlung-von-Patienten-mit-43346780/?utm_source=whatsapp&utm_medium=social&utm_campaign=share